Neuroendocrine differentiation in the setting of prostatic carcinoma: Contemporary assessment of a consecutive series Journal Article
| Authors: | Gopalan, A.; Al-Ahmadie, H.; Chen, Y. B.; Sarungbam, J.; Sirintrapun, S. J.; Tickoo, S. K.; Reuter, V. E.; Fine, S. W. |
| Article Title: | Neuroendocrine differentiation in the setting of prostatic carcinoma: Contemporary assessment of a consecutive series |
| Abstract: | Aim: Clinicopathologic characterisation of a contemporary series of neuroendocrine (NE) differentiation in the setting of prostatic carcinoma (PCa) was examined. Methods and results: We reviewed institutional databases for in-house cases with a history of PCa and histopathologic evidence of NE differentiation during the disease course. In all, 79 cases were identified: 32 primary and 47 metastases. Metastatic lesions were in liver (n = 15), lymph node (n = 9), bone (n = 6), lung (n = 3), brain (n = 1), and other sites (n = 13). In all, 63 of 76 (82%) cases with NE differentiation and available history were posttherapy: six postradiation therapy (RT), 24 post- androgen–deprivation therapy (ADT), and 33 post-RT + ADT. Morphologic assessment (n = 79): (i) 23 pure small-cell/high-grade NE carcinoma (HGNEC): 20/23 metastatic; (ii) 10 combined high-grade PCa and small-cell/HGNEC: 9/10 primary; (iii) 15 PCa with diffuse NE immunohistochemistry (IHC) marker positivity/differentiation, associated with nested to sheet-like growth of cells with abundant cytoplasm and prominent nucleoli, yet diffuse positivity for at least one prostatic and one NE IHC marker: all metastatic; (iv) 11 PCa with patchy NE differentiation, displaying more than single-cell positivity for NE IHC: five primary / six metastatic; (v) nine PCa with focal NE marker positive cells: four primary / five metastatic; (vi) 11 PCa with ‘Paneth cell-like’ change: all primary. Conclusions: In this contemporary series, the majority of NE differentiation in the setting of PCa was seen posttherapy. We highlight the tendencies of small-cell/HGNEC and PCa with diffuse NE differentiation by IHC to occur in metastatic settings, while morphologically combined high-grade PCa + small-cell/HGNEC and ‘Paneth cell-like’ change occur in primary disease. © 2022 John Wiley & Sons Ltd. |
| Keywords: | immunohistochemistry; pathology; prostatic neoplasms; prostate; prostate tumor; androgen antagonists; carcinoma; antiandrogen; small cell carcinoma; carcinoma, neuroendocrine; carcinoma, small cell; neuroendocrine; small-cell; humans; human; male |
| Journal Title: | Histopathology |
| Volume: | 81 |
| Issue: | 2 |
| ISSN: | 0309-0167 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2022-08-01 |
| Start Page: | 246 |
| End Page: | 254 |
| Language: | English |
| DOI: | 10.1111/his.14707 |
| PUBMED: | 35758203 |
| PROVIDER: | scopus |
| PMCID: | PMC9327588 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 August 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
486Tickoo -
418Gopalan -
400Chen -
464Fine -
663Al-Ahmadie -
1229Reuter -
202Sirintrapun -
90Sarungbam
Related MSK Work